BridgeMD
The dosage of antithrombotics adjusted to body weight
EU CTIS ID: 2024-518890-33-00
What this study is testing
To determine if clopidogrel treatment can be optimized in patients with a low or high body weight/Body Mass Index (BMI) compared to patients with a normal body weight/BMI by adjusting the dosage of clopidogrel and evaluating platelet reactivity measured using the VerifyNow.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients, male or female, ≥18 years of age
- Patients treated for chronic coronary syndrome with clopidogrel 75mg QD (aspirin 100mg QD)
- Patients must be treated with clopidogrel 75mg for at least one month
- Patients must give consent by means of a signed informed consent
You likely can't join if
- Contra-indication for aspirin
- Suboptimal stent placement as determined by the cardiologist
- Patients at increased risk of bleeding with two of the following characteristics: liver cirrhosis with portal hypertension, enhanced bleeding tendency, active malignancy in the past 12 months, thrombocytopenia, major surgery in the past month, spontaneous intracerebral haemorrhage, traumatic intracerebral haemorrhage in the past 12 months, major bleeding requiring hospitalisation or blood transfusion in the past month, ischaemic cerebrovascular accident in the past 5 months.
- Known with established stent thrombosis
- Contra-indication for clopidogrel or prasugrel
- Occurrence of an ischemic event after percutaneous coronary intervention or acute coronary syndrome (stroke, myocardial infarction, or coronary revascularization)
See the full eligibility criteria
- Patients, male or female, ≥18 years of age
- Patients treated for chronic coronary syndrome with clopidogrel 75mg QD (aspirin 100mg QD)
- Patients must be treated with clopidogrel 75mg for at least one month
- Patients must give consent by means of a signed informed consent
- Contra-indication for aspirin
- Suboptimal stent placement as determined by the cardiologist
- Patients at increased risk of bleeding with two of the following characteristics: liver cirrhosis with portal hypertension, enhanced bleeding tendency, active malignancy in the past 12 months, thrombocytopenia, major surgery in the past month, spontaneous intracerebral haemorrhage, traumatic intracerebral haemorrhage in the past 12 months, major bleeding requiring hospitalisation or blood transfusion in the past month, ischaemic cerebrovascular accident in the past 5 months.
- Known with established stent thrombosis
- Contra-indication for clopidogrel or prasugrel
- Occurrence of an ischemic event after percutaneous coronary intervention or acute coronary syndrome (stroke, myocardial infarction, or coronary revascularization)
- Presence of unstable angina complaints
- Presence of two CYP2C19 Loss-of-function (LOF) alleles (*2 or *3)
- Scheduled for cardiac valve surgery
- Indication for chronic oral anticoagulants
- Expected life span of less than one year
- Pregnancy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.